Mom Putting Covid-19 in Its Place (in One Weekend with One Team)

EMERYVILLE, Calif., March 5, 2020 /PRNewswire/ — After the first case was discovered near her home and her family, Heather Sittig, CEO of Relola.com knew something had to be done to stop spread the disease. Instead of just thinking about it she declared to her family that night she was going to put Covid-19 in its place. The next day she told a few team members at work and the result, the whole team work all night and all day during the weekend to create a free site not just for California, her home, but for the world.

What they created is a map that allows people to report anonymously how they are feeling if they have any target symptoms, where they have traveled in the past 14 days and if they have been in contact with someone who has a confirmed case of Covid-19. All good Moms know forewarned is forearmed and with this advance notice people could elect to self-quarantine and avoid exposure to the virus. In less than an hour and with no media, hundreds had signed up, and it grows everyone minute, as we all know by sharing information, we can prevent the spread of the disease and save lives. Here it is – use it – share it

Relola.com is headquartered in Emeryville, CA. Founded in 2015, Relola is a provider of location-based enterprise solutions that enable organizations to own and broadcast organic content generated by their networks. 

For more information text or call Heather at +1-510-282-1696 or email her at 235493@email4pr.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/mom-putting-covid-19-in-its-place-in-one-weekend-with-one-team-301017414.html

SOURCE Relola, Inc.

user

Recent Posts

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

4 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

4 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

4 hours ago